• Explore /
  • Poster
  • / Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).

Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).

Abstract Poster

Authors

Martin Reck

Martin Reck

LungenClinic Grosshansdorf, German Center for Lung Research, Grosshansdorf, Germany

Martin Reck , Tom Karagiannis , Thomas Wehler , Mikhail Shtivelband , Jose-Luis Gonzalez-Larriba , Jeffrey Rothenstein , Martin Frueh , Yu Deng , Ariel Lopez-Chavez , Alan Sandler , Mark A. Socinski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02366143

Citation

J Clin Oncol 36, 2018 (suppl; abstr 9047)

DOI

10.1200/JCO.2018.36.15_suppl.9047

Abstract #

9047

Poster Bd #

370

Abstract Disclosures

Similar Posters

First Author: Filippo de Marinis

First Author: Ana Oaknin

Poster

2019 ASCO Annual Meeting

IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets).

IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets).

First Author: Mark A. Socinski

First Author: Vassiliki Papadimitrakopoulou